In Situ Metabolomics of Cortisol-Producing Adenomas

  • Masanori Murakami
    Medizinische Klinik und Poliklinik IV, Klinikum der Universitt, Ludwig-Maximilians-Universitt Mnchen , Munich , Germany
  • Na Sun
    Research Unit Analytical Pathology, Helmholtz Zentrum Mnchen, German Research Center for Environmental Health (GmbH) , Neuherberg , Germany
  • Fengxia Li
    Research Unit Analytical Pathology, Helmholtz Zentrum Mnchen, German Research Center for Environmental Health (GmbH) , Neuherberg , Germany
  • Annette Feuchtinger
    Research Unit Analytical Pathology, Helmholtz Zentrum Mnchen, German Research Center for Environmental Health (GmbH) , Neuherberg , Germany
  • Celso Gomez-Sanchez
    Division of Endocrinology, G.V. (Sonny) Montgomery VA Medical Center and the University of Mississippi Medical Center , Jackson, MS
  • Martin Fassnacht
    Department of Internal Medicine I, Division of Endocrinology and Diabetology, University Hospital Wrzburg, University of Wrzburg , Wrzburg , Germany
  • Martin Reincke
    Medizinische Klinik und Poliklinik IV, Klinikum der Universitt, Ludwig-Maximilians-Universitt Mnchen , Munich , Germany
  • Irina Bancos
    Division of Endocrinology, Mayo Clinic , Rochester, MN
  • Axel Walch
    Research Unit Analytical Pathology, Helmholtz Zentrum Mnchen, German Research Center for Environmental Health (GmbH) , Neuherberg , Germany
  • Matthias Kroiss
    Medizinische Klinik und Poliklinik IV, Klinikum der Universitt, Ludwig-Maximilians-Universitt Mnchen , Munich , Germany
  • Felix Beuschlein
    Medizinische Klinik und Poliklinik IV, Klinikum der Universitt, Ludwig-Maximilians-Universitt Mnchen , Munich , Germany

抄録

<jats:title>Received June 8, 2022; accepted October 11, 2022</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>Recent advances in omics techniques have allowed detailed genetic characterization of cortisol-producing adrenal adenoma (CPA). In contrast, the pathophysiology of CPAs has not been elucidated in detail on the level of tumor metabolic alterations.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>The current study conducted a comprehensive mass spectrometry imaging (MSI) map of CPAs in relation to clinical phenotypes and immunohistochemical profiles of steroidogenic enzymes. The study cohort comprised 46 patients with adrenal tumors including CPAs (n 35) and nonfunctional adenomas (n 11).</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>Severity of cortisol hypersecretion was significantly correlated with 29 metabolites (adjusted P 0.05). Adrenal androgens derived from the classic androgen pathway were inversely correlated with both cortisol secretion (rs 0.41, adjusted P 0.035) and CYP11B1 expression (rs 0.77, adjusted P 2.00E-08). The extent of cortisol excess and tumor CYP11B1 expression further correlated with serotonin (rs 0.48 and 0.62, adjusted P 0.008 and 2.41E-05). Tumor size was found to be correlated with abundance of 13 fatty acids (adjusted P 0.05) and negatively associated with 9 polyunsaturated fatty acids including phosphatidic acid 38:8 (rs 0.56, adjusted P 0.009).</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions</jats:title> <jats:p>MSI reveals novel metabolic links between endocrine function and tumorigenesis, which will further support the understanding of CPA pathophysiology.</jats:p> </jats:sec>

収録刊行物

  • Clinical Chemistry

    Clinical Chemistry 69 (2), 149-159, 2022-12-21

    Oxford University Press (OUP)

参考文献 (44)*注記

もっと見る

関連プロジェクト

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ